Satoprodil Phase 2 Depression Trials: Why the GluN2B Strategy Failed to Beat Placebo
Two randomized phase 2 trials published in Neuropsychopharmacology on September 5, 2026 found that satoprodil, also known as BI 1569912, did not reduce depressive symptoms beyond placebo when used alone or alongside standard antidepressants. The result is an important test of non-ketamine glutamate drug development: the compound was generally tolerated, but the GluN2B-selective mechanism did not deliver a meaningful antidepressant signal in these studies.
